Jiandong F. Huo

Bio Island
Guangzhou, 510320, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications

A Precision-Engineered DC-Targeting mRNA-LNP Neoantigen Vaccine Elicits Stronger T Cell Responses and Exhibits Superior Tumor Control.

A Precision-Engineered DC-Targeting mRNA-LNP Neoantigen Vaccine Elicits Stronger T Cell Responses and Exhibits Superior Tumor Control.

Journal: Vaccines
Published: January 22, 2026

Author Correction: An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters.

Author Correction: An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters.

Journal: NPJ vaccines
Published: July 10, 2025

An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters.

An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters.

Journal: NPJ vaccines
Published: February 08, 2025

Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.

Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.

Journal: Open biology
Published: June 05, 2024

Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models.

Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: May 25, 2023

Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.

Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.

Journal: Cell reports
Published: January 09, 2023

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2.

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2.

Journal: Signal transduction and targeted therapy
Published: January 03, 2023

Antibody agonists trigger immune receptor signaling through local exclusion of receptor-type protein tyrosine phosphatases.

Antibody agonists trigger immune receptor signaling through local exclusion of receptor-type protein tyrosine phosphatases.

Journal: Immunity
Published: October 11, 2022

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.

Journal: Nature communications
Published: October 06, 2022

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.

Journal: Cell discovery
Published: September 20, 2022

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75.

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75.

Journal: Cell reports
Published: September 14, 2022

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum.

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum.

Journal: Cell discovery
Published: August 01, 2022
Showing 1-12 of 41

Last Updated: 09/26/2026